drugset / Trial / NCT02354703
Pharmacogenetic Study of Ondansetron in Alcohol Use Disorder
Phase 2
Completed
293 enrolled
University of Maryland, Baltimore
University of Pennsylvania · collab
RandomizedFactorialQuadruple-blindTreatment
Summary
The primary study objective is to determine the efficacy of ondansetron (0.33 mg twice daily) administered orally for a period of 16 weeks in reducing risky drinking among currently drinking subjects with alcohol use disorder who have selected genotypes at the serotonin transporter and receptor genes. The secondary objective is to assess the safety and tolerability of ondansetron in subjects with alcohol use disorder who have selected genotypes at the serotonin transporter and receptor genes.
Timeline
- Start
- 2015-08
- Primary completion
- 2020-03-31
- Completion
- 2020-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ondansetron | Other / unclassified | 0.33 mg | Oral |